Cadence Pharma launches Ofirmev in US
Cadence Pharma received the US Food and Drug Administration (FDA) approval for Ofirmev in November 2010 for the management of mild to moderate pain, the management of moderate
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Pharmstandard is a Russian pharmaceutical company focused in R&D and production of the medicinal products. Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC Pharmstandard-Leksredstva in Kursk, JSC Pharmstandard-UfaVITA